Tags

Type your tag names separated by a space and hit enter

Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Vaccine. 2011 Oct 26; 29(46):8330-7.V

Abstract

In this study, we evaluated the immunogenicity and protective efficacy of a candidate attenuated H5N1 pre-pandemic influenza vaccine of clade 2.3.4, rgAnhui, which was reverse genetically generated from highly virulent A/Anhui/01/2005 (H5N1) wild-type virus. When a low-dose antigen (0.3μg HA) vaccine was combined with aluminum hydroxide adjuvant, virus neutralization and anti-HA IgG antibodies induced in the sera of vaccinated mice showed similar levels as those in mice vaccinated with non-adjuvanted high-dose antigen (3μg HA) vaccine. Serum antibodies had broad reactivity against highly pathogenic H5N1 viruses of both homologous and heterologous clades. All mice vaccinated with adjuvanted and non-adjuvanted rgAnhui vaccines at low and high antigen doses survived, without any significant weight loss, lethal challenge infection with homologous clade 2.3.4 viruses, including antigenic variant virus and heterologous clade 2.1.3. Mice vaccinated with low-dose antigen without adjuvant, however, exhibited 20% and 60% survival rates against clade 1 and clade 2.2 viruses, respectively; but, addition of adjuvant improved these rates to 80% and 100%, respectively. The data strongly suggest that aluminum hydroxide-adjuvanted rgAnhui vaccine can elicit broad cross-reactive and protective immunities against homologous and heterologous clades, and that the rgAnhui vaccine is a useful pre-pandemic H5N1 vaccine.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Harada Y
Influenza Virus Research Center, National Institute of Infectious Diseases, Musashi-Murayama, Tokyo, Japan.
Ninomiya-Mori A
No affiliation info available
Takahashi Y
No affiliation info available
Shirakura M
No affiliation info available
Kishida N
No affiliation info available
Kageyama T
No affiliation info available
Tada Y
No affiliation info available
Tashiro M
No affiliation info available
Odagiri T
No affiliation info available

MeSH

Adjuvants, ImmunologicAluminum HydroxideAnimalsAntibodies, NeutralizingAntibodies, ViralBody WeightCross ProtectionCross ReactionsFemaleImmunoglobulin GInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesMiceMice, Inbred BALB COrthomyxoviridae InfectionsSurvival AnalysisVaccines, Synthetic

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21911027

Citation

Harada, Yuichi, et al. "Inactivated and Adjuvanted Whole-virion Clade 2.3.4 H5N1 Pre-pandemic Influenza Vaccine Possesses Broad Protective Efficacy Against Infection By Heterologous Clades of Highly Pathogenic H5N1 Avian Influenza Virus in Mice." Vaccine, vol. 29, no. 46, 2011, pp. 8330-7.
Harada Y, Ninomiya-Mori A, Takahashi Y, et al. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine. 2011;29(46):8330-7.
Harada, Y., Ninomiya-Mori, A., Takahashi, Y., Shirakura, M., Kishida, N., Kageyama, T., Tada, Y., Tashiro, M., & Odagiri, T. (2011). Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine, 29(46), 8330-7. https://doi.org/10.1016/j.vaccine.2011.08.091
Harada Y, et al. Inactivated and Adjuvanted Whole-virion Clade 2.3.4 H5N1 Pre-pandemic Influenza Vaccine Possesses Broad Protective Efficacy Against Infection By Heterologous Clades of Highly Pathogenic H5N1 Avian Influenza Virus in Mice. Vaccine. 2011 Oct 26;29(46):8330-7. PubMed PMID: 21911027.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. AU - Harada,Yuichi, AU - Ninomiya-Mori,Ai, AU - Takahashi,Yoshimasa, AU - Shirakura,Masayuki, AU - Kishida,Noriko, AU - Kageyama,Tsutomu, AU - Tada,Yoshikazu, AU - Tashiro,Masato, AU - Odagiri,Takato, Y1 - 2011/09/10/ PY - 2011/06/21/received PY - 2011/08/08/revised PY - 2011/08/18/accepted PY - 2011/9/14/entrez PY - 2011/9/14/pubmed PY - 2012/2/9/medline SP - 8330 EP - 7 JF - Vaccine JO - Vaccine VL - 29 IS - 46 N2 - In this study, we evaluated the immunogenicity and protective efficacy of a candidate attenuated H5N1 pre-pandemic influenza vaccine of clade 2.3.4, rgAnhui, which was reverse genetically generated from highly virulent A/Anhui/01/2005 (H5N1) wild-type virus. When a low-dose antigen (0.3μg HA) vaccine was combined with aluminum hydroxide adjuvant, virus neutralization and anti-HA IgG antibodies induced in the sera of vaccinated mice showed similar levels as those in mice vaccinated with non-adjuvanted high-dose antigen (3μg HA) vaccine. Serum antibodies had broad reactivity against highly pathogenic H5N1 viruses of both homologous and heterologous clades. All mice vaccinated with adjuvanted and non-adjuvanted rgAnhui vaccines at low and high antigen doses survived, without any significant weight loss, lethal challenge infection with homologous clade 2.3.4 viruses, including antigenic variant virus and heterologous clade 2.1.3. Mice vaccinated with low-dose antigen without adjuvant, however, exhibited 20% and 60% survival rates against clade 1 and clade 2.2 viruses, respectively; but, addition of adjuvant improved these rates to 80% and 100%, respectively. The data strongly suggest that aluminum hydroxide-adjuvanted rgAnhui vaccine can elicit broad cross-reactive and protective immunities against homologous and heterologous clades, and that the rgAnhui vaccine is a useful pre-pandemic H5N1 vaccine. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21911027/Inactivated_and_adjuvanted_whole_virion_clade_2_3_4_H5N1_pre_pandemic_influenza_vaccine_possesses_broad_protective_efficacy_against_infection_by_heterologous_clades_of_highly_pathogenic_H5N1_avian_influenza_virus_in_mice_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01361-2 DB - PRIME DP - Unbound Medicine ER -